JPMorgan Chase & Co. Reaffirms “Neutral” Rating for GlaxoSmithKline (LON:GSK)

GlaxoSmithKline (LON:GSK)‘s stock had its “neutral” rating reaffirmed by investment analysts at JPMorgan Chase & Co. in a report released on Friday, Digital Look reports.

Other equities analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,350 ($18.32) price target on shares of GlaxoSmithKline in a research note on Wednesday, January 5th. The Goldman Sachs Group set a GBX 2,000 ($27.15) price target on shares of GlaxoSmithKline in a research note on Friday, January 7th. Liberum Capital reiterated a “buy” rating and issued a GBX 1,700 ($23.08) price target on shares of GlaxoSmithKline in a research note on Tuesday, December 14th. Morgan Stanley lowered their target price on shares of GlaxoSmithKline from GBX 1,565 ($21.24) to GBX 1,555 ($21.11) and set an “equal weight” rating on the stock in a research report on Thursday, October 7th. Finally, Credit Suisse Group set a GBX 1,400 ($19.00) target price on shares of GlaxoSmithKline in a research report on Thursday, October 28th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of GBX 1,591.80 ($21.61).

Shares of GlaxoSmithKline stock opened at GBX 1,641 ($22.28) on Friday. The firm has a market capitalization of £82.57 billion and a P/E ratio of 19.24. GlaxoSmithKline has a 52 week low of GBX 1,190.80 ($16.16) and a 52 week high of GBX 1,650.60 ($22.41). The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 117.74. The firm’s 50 day moving average is GBX 1,583.52 and its two-hundred day moving average is GBX 1,489.71.

In related news, insider Hal Barron purchased 2,422 shares of the firm’s stock in a transaction that occurred on Monday, November 22nd. The stock was purchased at an average cost of GBX 2,065 ($28.03) per share, with a total value of £50,014.30 ($67,889.64).

GlaxoSmithKline Company Profile

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

See Also: Understanding and Trading Breakout Stocks

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.